Hey everyone. I've been on semaglutide 1.0 mg weekly for about four months now and the weight loss has been solid (~22 lbs), but the GI side effects are brutal. Persistent nausea, some upper abdominal discomfort, and I suspect I'm developing mild gastritis based on the burning sensation after meals.

I've been reading about BPC-157 (Body Protection Compound) and its gastroprotective properties. The peptide is derived from human gastric juice and there's a decent body of preclinical literature showing it accelerates healing of GI mucosa.

Has anyone here stacked BPC-157 with their GLP-1 RA? Specifically interested in:

• Did it reduce GI side effects?
• What dose and route did you use?
• Any concerns about peptide interactions?

Appreciate any experience reports. Trying to stay on sema but the gut issues are making compliance hard.

I ran BPC-157 alongside tirzepatide for about 8 weeks specifically for this reason. Here's my take:

The research basis is actually pretty solid for GI applications. Sikiric et al. have published extensively on this — their 2018 review in Current Pharmaceutical Design (PMID: 29737246) covers the cytoprotective mechanisms. BPC-157 upregulates growth factor expression (EGF, VEGF), modulates the NO system, and has demonstrated mucosal protection in multiple animal models of gastric ulceration.

What dose and route did you use?

I used 250 mcg subcutaneous twice daily (morning and evening), injected in the abdominal area. Some people go with 500 mcg BID but I found the lower dose sufficient. Ran it for 8 weeks on, 4 weeks off.

Within about 10 days, the post-meal burning was noticeably reduced. Nausea from tirze didn't completely disappear but went from a 6/10 to maybe a 3/10. Could have been placebo, but the timeline was consistent.

No interactions that I could detect — appetite suppression from tirze remained strong, blood glucose stayed well-controlled. I did get baseline and follow-up liver panels and everything was clean.

Good topic. I want to add some mechanistic context here because I think it matters for understanding why this stack might make sense.

GLP-1 receptor agonists slow gastric emptying — that's a feature, not a bug, but it does increase the duration of acid exposure to the gastric mucosa, particularly in the antrum. If you already have subclinical inflammation or H. pylori colonization, the prolonged gastric retention can exacerbate things.

BPC-157's mechanism is somewhat unique among gastroprotective agents. Unlike PPIs which just suppress acid, BPC-157 appears to work through the FAK-paxillin pathway to promote cell migration and wound healing at the mucosal level (see Seiwerth et al., J Physiol Pharmacol, 2017, PMID: 29151081). It also interacts with the dopaminergic and serotonergic systems, which could theoretically help with the nausea component.

That said, a few caveats:

1. Nearly all the research is preclinical. There are no published human RCTs for BPC-157 in any indication.
2. The doses used in animal studies (10 mcg/kg in rats) don't translate linearly to human dosing — the 250-500 mcg range people use is largely empirical.
3. If you genuinely have gastritis, get scoped. Don't self-treat with peptides when you might need actual medical intervention.

With those disclaimers, anecdotally I've heard enough positive reports in this specific context that I think it's worth investigating.

Appreciate that breakdown. I should mention I did see my GI doc and he put me on pantoprazole 40 mg, which helped some but not enough. He was dismissive when I mentioned peptides but also said "if it's not hurting you, whatever."

One follow-up: does the route really matter? I've seen oral BPC-157 caps (usually called "stable BPC" or similar) marketed specifically for GI applications. The logic being that oral delivery targets the GI tract directly.

Route is actually a great question and somewhat debated. The argument for oral is intuitive — deliver the peptide directly to the GI mucosa where you want the effect. And there is some support for this: the original Sikiric studies in rats used both oral and IP administration and found GI effects with both routes.

The counterargument is bioavailability. BPC-157 is a 15-amino acid peptide, and most peptides get degraded by pepsin and trypsin in the GI tract. The "stable" oral formulations usually use some kind of enteric coating or arginine salt form (BPC-157-arginine) to improve survival through the stomach.

My personal approach: I used subQ but added oral BPC caps for the first 2 weeks when GI symptoms were worst. Belt and suspenders. Hard to say which was doing the heavy lifting, but the combination worked for me.

If you're already doing semaglutide injections, adding one more subQ pin isn't a big deal logistically. 29g insulin syringe, barely feel it. 🤷